St. Louis, Missouri -- Biotechnology company Confluence Life Sciences has received $4.8 million in new equity venture capital, according to an SEC regulatory filing.
Confluence is developing what it calls "novel kinase inhibitors for use in human and animal healthcare".
These inhibitors have the promise to target key enzymes involved in the regulation of cancer growth and in the modulation of chronic inflammation.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
16 investors participated in the offering.
Confluence is still seeking $600,000 in additional equity investment, according to the filing.